Chemomab Therapeutics
CMMB
9 hedge funds and large institutions have $2.28M invested in Chemomab Therapeutics in 2019 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
0% more funds holding
Funds holding: 9 → 9 (0)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
78% less capital inflows, than outflows
Capital inflows: $200K | Capital outflows: $924K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Meitav Investment House
Bene-Beraq,
Israel
|
+$46.3K |
| 2 |
Virtu Financial
New York
|
+$39.7K |
| 3 |
Morgan Stanley
New York
|
+$33.1K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$972 |
| 5 |
Tower Research Capital (TRC)
New York
|
+$972 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIC
AWM Investment Company
New York
|
-$448K |
| 2 |
RTW Investments
New York
|
-$233K |
| 3 |
Kennedy Capital Management
St Louis,
Missouri
|
-$214K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$23.1K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$6K |
CMMB Hedge Fund Activity: Q3 2019 in Review
9 of the 4,576 institutional investors tracked by Wall St. Rank reported a position in Chemomab Therapeutics (CMMB) for Q3 2019, worth a combined $2.28M — down 56% from $5.22M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new CMMB positions and 3 closed out — a net gain of 1 holder — while 2 added to existing stakes and 2 trimmed.
The largest buyer was Meitav Investment House, adding an estimated $46.3K. The largest seller was AWM Investment Company, exiting entirely with an estimated $448K sold.
- 9 institutional investors held Chemomab Therapeutics (CMMB) as of Q3 2019, unchanged from Q2 2019.
- Funds reported $2.28M of Chemomab Therapeutics stock for Q3 2019, down 56% quarter-over-quarter.
- 4 funds opened new Chemomab Therapeutics positions in Q3 2019 and 3 closed out, a net change of +1 holder.
- The largest Chemomab Therapeutics buyer in Q3 2019 was Meitav Investment House, an estimated $46.3K added.
- The largest Chemomab Therapeutics seller in Q3 2019 was AWM Investment Company, an estimated $448K sold.
Based on aggregated 13F filings for Q3 2019.